ReviewPharmacoEconomics - open2025
Cost-Effectiveness Analyses of Adolescent- and Young-Adult-Focused HIV Interventions Incorporating HIV Transmission: a Scoping Review of Modeling Methods and Proposed Guidance.
Review in PharmacoEconomics - open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Retractions of Health Economic Evaluations: A Systematic Review.PharmacoEconomics - open · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAdolescents and young adults (AYA) are disproportionately affected by human immunodeficiency virus (HIV) globally, with high-burden population subgroups differing across regions. Cost-effectiveness modeling analyses of AYA-focused HIV interventions have provided vital information to policy makers by projecting long-term health and economic impacts of interventions' effects on reduced HIV transmission. To provide a broad overview of available modeling approaches and identify gaps in methods reporting, we evaluated modeling methodologies used in AYA-focused cost-effectiveness analyses incorporating HIV transmission.
methodsWe searched PubMed, Embase, and Web of Science for peer-reviewed articles that were published January 2006 to August 2023 and described models that considered HIV transmission in estimating cost-effectiveness of AYA-focused HIV prevention interventions. We extracted selected study characteristics, transmission model properties, and methods to estimate long-term health and economic outcomes. We assessed study quality using published guidelines.
resultsAmong 42 studies, 38% included individuals assigned male or female sex at birth, 19% included females only, and 43% included males only; 24% focused on AYA only; 88% were set in Africa; and 7% were restricted to certain population subgroups. The most common population subgroups examined were women who have transactional sex (24%) and men who have sex with men (17%). Most (88%) studied primary prevention interventions for people at risk of HIV; 29% examined secondary prevention interventions including treatment and testing. Most (98%) assessed incremental cost-effectiveness ratios (ICERs) were defined as incremental cost per incremental life year (either quality-adjusted or disability-adjusted), or cost per infection averted, or both. Of 24 different transmission models identified with distinct structures, 59% were dynamic. Of 20 studies that translated averted infections into long-term health benefit, 55% used their transmission models directly through assigning health utilities to modeled states. A total of 30 studies converted averted infections into long-term cost savings, among which, 73% used their transmission models directly by assigning costs to modeled states. Fewer than half captured age-specific sexual and care-engagement behaviors. Important gaps in quality included incomplete reporting of model validation and calibration results.
conclusionsWe identified heterogeneous modeling approaches in cost-effectiveness analyses of AYA-focused HIV interventions incorporating transmission. Reporting of key elements could be improved. We propose additional criteria that could clarify choices around modeling approaches and strengthen the reporting of model validation and calibration results.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.